We are live on
!
Find out more
TLP
Tri Locum Partners Portfolio holdings
AUM
$713M
1-Year Est. Return
68.92%
This Fund
S&P 500
This Quarter
Est. Return
+11.94%
1 Year Est. Return
+68.92%
3 Year Est. Return
+377.81%
5 Year Est. Return
+1,289.15%
10 Year Est. Return
–
AUM
$403M
AUM Growth
+$128M
(+46%)
Cap. Flow
+$111M
Cap. Flow
% of AUM
27.45%
Top 10 Holdings %
Top 10 Hldgs %
71.78%
Holding
84
New
19
Increased
11
Reduced
3
Closed
50
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Regeneron Pharmaceuticals
REGN
|
+$26.4M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$24.8M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$24.1M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
+$18.2M |
| 5 |
NUAN
Nuance Communications, Inc.
NUAN
|
+$15.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$20.7M |
| 2 |
Viatris
VTRS
|
+$19.6M |
| 3 |
Labcorp
LH
|
+$11M |
| 4 |
CCXI
ChemoCentryx, Inc.
CCXI
|
+$10.3M |
| 5 |
Zai Lab
ZLAB
|
+$8.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.34% |
| 2 | Technology | 3.61% |
| 3 | Communication Services | 0% |
| 4 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WBA
1
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $42.3M | 10.48% |
+770,000
| New | +$38.1M |
|
|
WBA
2
PUT
DELISTED
Walgreens Boots Alliance
WBA
| $42.3M | 10.48% |
+770,000
| New | +$38.1M |
|
|
3
Regeneron Pharmaceuticals
REGN
$70.9B
| $30.6M | 7.59% |
64,705
+54,282
| +521% | +$26.4M |
|
4
Medtronic
MDT
$106B
| $28.3M | 7.02% |
239,644
+35,506
| +17% | +$4.16M |
|
5
Johnson & Johnson
JNJ
$609B
| $27.7M | 6.87% |
168,634
+6,001
| +4% | +$971K |
|
|
HZNP
6
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $27M | 6.7% |
+293,426
| New | +$24.8M |
|
7
Baxter International
BAX
$11.7B
| $26.5M | 6.57% |
314,136
+15,415
| +5% | +$1.22M |
|
|
8
Bristol-Myers Squibb
BMY
$124B
| $24.7M | 6.12% |
390,992
+386,795
| +9,216% | +$24.1M |
|
|
WBA
9
DELISTED
Walgreens Boots Alliance
WBA
| $22M | 5.44% |
399,842
-41,482
| -9% | -$2.05M |
|
|
10
Jazz Pharmaceuticals
JAZZ
$15.5B
| $18.1M | 4.5% |
+110,382
| New | +$18.2M |
|
11
Humana
HUM
$48B
| $15M | 3.71% |
+35,693
| New | +$14.2M |
|
|
NUAN
12
DELISTED
Nuance Communications, Inc.
NUAN
| $14.6M | 3.61% |
+333,482
| New | +$15.3M |
|
13
Eli Lilly
LLY
$1.05T
| $9.02M | 2.24% |
48,299
-7,222
| -13% | -$1.41M |
|
|
NMTR
14
DELISTED
9 Meters Biopharma
NMTR
| $7.77M | 1.93% |
332,217
+262,676
| +378% | +$8.07M |
|
15
TG Therapeutics
TGTX
$8.4B
| $7.16M | 1.78% |
148,620
+78,688
| +113% | +$3.78M |
|
16
Protagonist Therapeutics
PTGX
$9.06B
| $6.66M | 1.65% |
257,086
-2,197
| -0.8% | -$55.6K |
|
|
MYOV
17
DELISTED
Myovant Sciences Ltd.
MYOV
| $6.61M | 1.64% |
321,101
+280,191
| +685% | +$6.38M |
|
|
TRIL
18
DELISTED
Trillium Therapeutics Inc.
TRIL
| $6.22M | 1.54% |
578,930
+282,092
| +95% | +$3.49M |
|
19
Aclaris Therapeutics
ACRS
$793M
| $4.14M | 1.03% |
+164,199
| New | +$3.21M |
|
20
Celldex Therapeutics
CLDX
$2.77B
| $4.05M | 1% |
+196,672
| New | +$4.52M |
|
21
Syndax Pharmaceuticals
SNDX
$2.02B
| $4.03M | 1% |
180,261
+61,428
| +52% | +$1.39M |
|
|
INFI
22
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $3.91M | 0.97% |
+1,210,863
| New | +$4.04M |
|
|
CASI
23
DELISTED
CASI Pharmaceuticals
CASI
| $3.6M | 0.89% |
+150,000
| New | +$4.21M |
|
24
Black Diamond Therapeutics
BDTX
$103M
| $3.47M | 0.86% |
142,911
+132,628
| +1,290% | +$3.58M |
|
|
SNCE
25
DELISTED
Science 37 Holdings, Inc. Common Stock
SNCE
| $3.04M | 0.75% |
15,000
| – | – |
|
Similar funds
DCM
AMPWP
DCM
IWP
LS
PCS
ACGDR
GEA
Tri Locum Partners's Q1 2021 Portfolio in Review
As of Q1 2021, Tri Locum Partners held 84 positions worth $403M, up 46% from $275M the previous quarter. Its ten largest holdings account for 72% of the portfolio.
Tri Locum Partners deployed $111M of net new capital in Q1 2021, opening 19 new positions and adding to 11 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 293,426 shares worth $27M.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 93% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Walgreens Boots Alliance, an estimated $2.05M trimmed.
- Tri Locum Partners's largest Q1 2021 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 293,426 shares worth $27M.
- Tri Locum Partners added most to Regeneron Pharmaceuticals in Q1 2021, an estimated $26.4M increase.
- Tri Locum Partners's biggest Q1 2021 reduction was Walgreens Boots Alliance, cutting an estimated $2.05M.
- Tri Locum Partners fully exited AbbVie in Q1 2021, selling an estimated $20.7M.
- Tri Locum Partners's ten largest holdings make up 72% of its $403M portfolio in Q1 2021.
- Tri Locum Partners opened 19 new positions and closed 50 in Q1 2021.
- Tri Locum Partners's portfolio value rose 46% quarter-over-quarter to $403M.
Based on Tri Locum Partners's 13F filing for Q1 2021, filed 17 May 2021.